Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease

Journal of Endocrinological Investigation

Volumn 37, Issue 3, 2014, Pages 261-268

  Russo, G T ^a   Giandalia, A ^a   Romeo, E L ^a   Marotta, M ^a   Alibrandi, A ^b   De Francesco, C ^a   Horvath, K V ^c   Asztalos, B ^c   Cucinotta, D ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Coronary heart disease; Creatine clearance; SdLDL; Type 2 diabetes; Women

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; LIPID;

ADULT; AGE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE CLEARANCE; DIET RESTRICTION; DIET THERAPY; DISEASE DURATION; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PREVALENCE; SMOKING HABIT; WAIST CIRCUMFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; FOLLOW UP; LIFESTYLE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS;

EID: 84900546646     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-013-0023-z     Document Type: Article

References (47)

1. Raza JA, Reinhart RA, Movahed A (2004) Ischemic heart disease in women and the role of hormone therapy. Int J Cardiol 96:7-19
2. Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120-126
3. Yusuf S, Hawken S, Ounpuu S, On behalf of the INTERHEART study investigators et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952
4. Huxley R, Barzi F, Woodward M (2006) Excess risk of fatal coronary heart disease associated with diabetes in men and women: metaanalysis of 37 prospective cohort studies. BMJ 332:73-78
5. Rivellese AA, Riccardi G, Vaccaro O (2010) Cardiovascular risk in women with diabetes. Nutr Metab Cardiovasc Dis 20:474-480
6. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
7. Grundy SM, Cleeman JI, Merz CN, For the Coordinating Committee of the National Cholesterol Education Program et al (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227-239
8. Fruchart JC, Sacks F, Hermans MP et al (2008) The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102 (10 Suppl): 1K-34K
9. Taskinen MR (2003) Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 46:733-749
10. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143
11. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334
12. Duncan BB, Schmidt MI, Pankow JS, Atherosclerosis Risk in Communities Study et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805
13. Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391-397
14. Pfützner A, Forst T (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8:28-36
15. Jager A, van Hinsbergh VW, Kostense PJ et al (2000) Increased levels of Soluble Vascular Cell Adhesion Molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes. The Hoorn Study. Diabetes 49:485-491
16. Russo GT, Cucinotta D (2003) Hyperhomocysteinemia and cardiovascular risk in diabetes mellitus. Ann Ist Super Sanita 39:153-163
17. Russo GT, Di Benedetto A, Magazzù D et al (2001) Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetol 48:95-101
18. Clarke R, Halsey J, Lewington S, B-Vitamin Treatment Trialists' Collaboration et al (2010) Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med 170:1622-1631
19. Rossi MC, Cristofaro MR, Gentile S, Lucisano G, Manicardi V, Mulas MF, Napoli A, Nicolucci A, Pellegrini F, Suraci C, Giorda C (2013) Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the AMD annals initiative. Diabetes Care 8 Jul [Epub ahead of print] PubMedPMID: 23835692
20. Franzini L, Ardigò D, Cavalot F, Miccoli R, Rivellese AA, Trovati M, Zavaroni I, Vaccaro O (2013) Women showworse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND. IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis 23(3):235-241
21. Solini A, Penno G, Bonora E, Renal Insufficiency And Cardiovascular Events (RIACE) Study Group et al (2012) Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care 35:143-149
22. Russo GT, Di Benedetto A, Alessi E et al (2008) Menopause modulates homocysteine levels in diabetic and non-diabetic women. J Endocrinol Invest 31:546-551
23. American Diabetes Association (2012) Standards of medical care in diabetes-2012. Diabetes Care 35(Suppl 1):S11-S63. doi:10.2337/dc12-s011
24. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 28:412-419
26. Nakajima K, Saito T, Tamura A (1993) Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71
27. Hirano T, Ito Y, Saegusa H, Yoshino G (2003) A novel and simple method for quantitation of small dense low density lipoprotein. J Lipid Res 44:2193-2201
28. Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V (2013) Gender medicine: a task for the third millennium. Clin Chem Lab Med 51:713-727
29. Avogaro A, Giorda C, Maggini M, Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità et al (2007) Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241-1247
30. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Circulation 106:3143-3421
31. Colhoun HM, Betteridge DJ, Durrington PN, CARDS investigators et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
32. Heart Protection Study Collaborative Group (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
33. Russo GT, Horvath KV, Di Benedetto A, Giandalia A, Cucinotta D, Asztalos B (2010) Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes. Atherosclerosis 210:294-301
34. Gruppo Annali Associazione Medici Diabetologi. Annali AMD 2012 - Analisi prospettica degli indicatori dell'Assistenza del diabete in Italia (2004-2011) ISBN 978-88-96489-08-06
35. Hirayama S, Miida T (2012) Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 414:215-224
36. Austin MA, Hokanson JE, Brunzell JD (1994) Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 5:395-403
37. Lamarche B, Lemieux I, Despres JP (1999) The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25:199-211
38. Matthan N, Jalbert SM, Lamon-Fava S et al (2005) TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Arterioscler Thromb Vasc Biol 25:1691-1696
39. Ai M, Otokozawa S, Asztalos BF et al (2010) Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem 56:967-976
40. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232
41. Muiesan ML, Ambrosioni E, Costa FV et al (2012) Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study. J Hypertens 30:2378-2386
42. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (2004) Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 27:2898-2904
43. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DE (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828
44. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM (1998) Insulin and risk of cardiovascular disease: a metaanalysis. Circulation 97:996-1001
45. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319-328
46. Kones R (2010) Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease - a perspective. Drug Des Devel Ther 4:383-441
47. Kaptoge S, Di Angelantonio E, Lowe G et al (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132-140